%D8%AF%D9%88%D9%84%D9%88%D9%83%D8%B3%D9%8A%D8%AA%D9%8A%D9%86%D8%AF%D9%88%D9%84%D9%88%DA%A9%D8%B3%D8%AA%DB%8C%D9%86Category:DuloxetineDuloxetinDuloxetinDuloxetineDuloxetina%D8%AF%D9%88%D9%84%D9%88%DA%A9%D8%B3%D8%AA%DB%8C%D9%86DuloksetiiniDulox%C3%A9tine%D7%93%D7%95%D7%9C%D7%95%D7%A7%D7%A1%D7%98%D7%99%D7%9FDuloxetinDuloxetina%E3%83%87%E3%83%A5%E3%83%AD%E3%82%AD%E3%82%BB%E3%83%81%E3%83%B3%EB%91%98%EB%A1%9D%EC%84%B8%ED%8B%B4%D0%94%D1%83%D0%BB%D0%BE%D0%BA%D1%81%D0%B5%D1%82%D0%B8%D0%BDDuloxetine%E0%AC%A1%E0%AD%81%E0%AC%B2%E0%AD%8B%E0%AC%95%E0%AD%8D%E0%AC%B8%E0%AD%87%E0%AC%9F%E0%AC%BF%E0%AC%A8DuloksetynaDuloxetina%D0%94%D1%83%D0%BB%D0%BE%D0%BA%D1%81%D0%B5%D1%82%D0%B8%D0%BDDuloksetinDuloksetinDuloxetin%D0%94%D1%83%D0%BB%D0%BE%D0%BA%D1%81%D0%B5%D1%82%D0%B8%D0%BDDuloxetineQ411932%E5%BA%A6%E6%B4%9B%E8%A5%BF%E6%B1%80
about
sameAs
P3364
Duloxetine, a Balanced Serotonin-Norepinephrine Reuptake Inhibitor, Improves Painful Chemotherapy-Induced Peripheral Neuropathy by Inhibiting Activation of p38 MAPK and NF-κBClinical meaningfulness of duloxetine's effect in Chinese patients with chronic pain due to osteoarthritis: post hoc analyses of a phase 3 randomized trialMaintenance of effect of duloxetine in Chinese patients with pain due to osteoarthritis: 13-week open-label extension dataDepressive symptomatology in a female patient with Tarlov cystAssociation between body mass index and response to duloxetine for aromatase inhibitor-associated musculoskeletal symptoms in SWOG S1202Possible Role of Cyclic AMP Response Element Binding/Brain-Derived Neurotrophic Factor Signaling Pathway in Mediating the Pharmacological Effects of Duloxetine against Methamphetamine Use-Induced Cognitive Impairment and Withdrawal-Induced Anxiety anLeveraging EEG for Antidepressant Prediction With Duloxetine and Bupropion
P921
Q1066311-DE8F32BA-42B0-49D4-9403-666D225FC3E8Q12135-0F23240A-AAC3-419D-A66F-6CDD1C413995Q133823-B55B3E6C-4C26-42A6-8932-3BA72864D9CCQ154430-5EE3BC24-22C4-4A44-BCDD-7B11B569D65AQ170990-A7AA7A62-ADFE-4DB4-94E7-884E68DFDBD8Q178190-F4A2F779-DCB0-41F3-8A48-98B47208F14AQ188638-C31A6EB6-6294-44D1-853A-6D227F36CE30Q202387-EF7F10E5-2CEE-4818-96DA-F483F2B56653Q42844-A20B7F0F-AC8B-4F07-A801-8B5FF9900C77Q540571-e49a4c27-496d-f197-cdf4-3472b0c926a6Q544006-24240E71-C33D-4CDA-84ED-8025B84EFB2BQ55781316-EF6BE6F1-DA86-41CE-BF07-97694DF59979Q845224-122E584A-3B39-4DC8-81A4-CA8840EA4687Q845224-5A22F1BC-0D88-418C-9610-F6FA4855A7AEQ935129-78EF0ABF-98E7-42FE-9C3B-5D5F84CC6780Q945238-1FC3AF32-E70A-40C2-8403-36056D8C59C8
P2176
description
antidepressivum
@da
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
name
(S)-duloksetyna
@pl
Duloksetin
@sh
Duloksetin
@sr
Duloxetin
@da
Duloxetin
@de
Duloxetin
@hu
Duloxetin
@sv
Duloxetine
@nl
Duloxetine
@vi
duloksetiini
@fi
type
label
(S)-duloksetyna
@pl
Duloksetin
@sh
Duloksetin
@sr
Duloxetin
@da
Duloxetin
@de
Duloxetin
@hu
Duloxetin
@sv
Duloxetine
@nl
Duloxetine
@vi
duloksetiini
@fi
altLabel
(3S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine
@en
(S)-duloxetine
@en
116539-59-4
@fr
116539-60-7
@fr
116817-13-1
@fr
C18H19NOS
@fr
C18H19NOS
@it
Cymbalta
@de
Cymbalta
@fr
Cymbalta
@pt
prefLabel
(S)-duloksetyna
@pl
Duloksetin
@sh
Duloksetin
@sr
Duloxetin
@da
Duloxetin
@de
Duloxetin
@hu
Duloxetin
@sv
Duloxetine
@nl
Duloxetine
@vi
duloksetiini
@fi